128 related articles for article (PubMed ID: 26501714)
1. Antireflux Surgery and Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.
Maret-Ouda J; Konings P; Lagergren J; Brusselaers N
Ann Surg; 2016 Feb; 263(2):251-7. PubMed ID: 26501714
[TBL] [Abstract][Full Text] [Related]
2. Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus.
Åkerström JH; Santoni G; von Euler Chelpin M; Ness-Jensen E; Kauppila JH; Holmberg D; Lagergren J
Gastroenterology; 2024 Jan; 166(1):132-138.e3. PubMed ID: 37690771
[TBL] [Abstract][Full Text] [Related]
3. Comment Regarding "Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus".
Zhang H
Gastroenterology; 2024 May; 166(5):943. PubMed ID: 37741421
[No Abstract] [Full Text] [Related]
4. Prevalence of Barrett's Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis.
Saha B; Vantanasiri K; Mohan BP; Goyal R; Garg N; Gerberi D; Kisiel JB; Singh S; Iyer PG
Clin Gastroenterol Hepatol; 2023 Oct; ():. PubMed ID: 37879525
[TBL] [Abstract][Full Text] [Related]
5. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies.
Rubenstein JH; Scheiman JM; Sadeghi S; Whiteman D; Inadomi JM
Am J Gastroenterol; 2011 Feb; 106(2):254-60. PubMed ID: 21139576
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Impact of Antireflux Treatment on Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus: Insights from a Mendelian Randomization Study.
Li Z; Yang K
Gastroenterology; 2024 May; 166(5):944-945. PubMed ID: 38246505
[No Abstract] [Full Text] [Related]
7. Treatment of esophageal adenocarcinoma in patients with a history of bariatric surgery.
Nobel T; Sewell M; Boerner T; Bains MS; Bott MJ; Gerdes H; Gray K; Nishimura M; Park BJ; Shah P; Sihag S; Jones DR; Molena D
J Gastrointest Surg; 2024 Apr; 28(4):337-342. PubMed ID: 38583881
[TBL] [Abstract][Full Text] [Related]
8. Population Based Time Trends in the Epidemiology and Mortality of Gastroesophageal Junction and Esophageal Adenocarcinoma.
Agarwal S; Bell MG; Dhaliwal L; Codipilly DC; Dierkhising RA; Lansing R; Gibbons EE; Leggett CL; Kisiel JB; Iyer PG
Dig Dis Sci; 2024 Jan; 69(1):246-253. PubMed ID: 37914889
[TBL] [Abstract][Full Text] [Related]
9. Use of antireflux medication after antireflux surgery.
Wijnhoven BP; Lally CJ; Kelly JJ; Myers JC; Watson DI
J Gastrointest Surg; 2008 Mar; 12(3):510-7. PubMed ID: 18071830
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori infection does not influence the progression from gastroesophageal reflux disease to Barrett's esophagus to esophageal adenocarcinoma.
Edhi A; Gangwani MK; Aziz M; Jaber F; Khan Z; Inamdar S; Thrift AP; Desai TK
Minerva Gastroenterol (Torino); 2024 May; ():. PubMed ID: 38727697
[TBL] [Abstract][Full Text] [Related]
11. Antireflux surgery to prevent the progression from Barrett's esophagus to esophageal adenocarcinoma: yes or no?
Patti MG; Herbella FA; Schlottmann F
J Gastrointest Oncol; 2023 Aug; 14(4):1916-1918. PubMed ID: 37720436
[No Abstract] [Full Text] [Related]
12. Antireflux Surgery Does Not Prevent Cancer in Barrett's Esophagus.
Lipham J; Kahrilas PJ
Gastroenterology; 2024 Jan; 166(1):21-23. PubMed ID: 37827438
[No Abstract] [Full Text] [Related]
13.
Polyzos SA; Zeglinas C; Artemaki F; Doulberis M; Kazakos E; Katsinelos P; Kountouras J
Ann Gastroenterol; 2018; 31(1):8-13. PubMed ID: 29333062
[TBL] [Abstract][Full Text] [Related]
14. Risk of Esophageal Adenocarcinoma After Bariatric Surgery: A Meta-Analysis of Retrospective Studies.
Zhu C; Liu W; Hu D; Peng L
Obes Surg; 2024 May; 34(5):1726-1736. PubMed ID: 38536625
[TBL] [Abstract][Full Text] [Related]
15. Lifestyle, WCRF/AICR Recommendations, and Esophageal Adenocarcinoma Risk: A Systematic Review of the Literature.
Nucci D; Marino A; Realdon S; Nardi M; Fatigoni C; Gianfredi V
Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684526
[TBL] [Abstract][Full Text] [Related]
16. Prebiotic proanthocyanidins inhibit bile reflux-induced esophageal adenocarcinoma through reshaping the gut microbiome and esophageal metabolome.
Weh KM; Howard CL; Zhang Y; Tripp BA; Clarke JL; Howell AB; Rubenstein JH; Abrams JA; Westerhoff M; Kresty LA
JCI Insight; 2024 Feb; 9(6):. PubMed ID: 38329812
[TBL] [Abstract][Full Text] [Related]
17. Extracellular miRNAs for the Management of Barrett's Esophagus and Esophageal Adenocarcinoma: A Systematic Review.
Inokuchi K; Ochiya T; Matsuzaki J
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33396321
[TBL] [Abstract][Full Text] [Related]
18. A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma.
Zaidi AH; Pratama MY; Omstead AN; Gorbonova A; Mansoor R; Melton-Kreft R; Jobe BA; Wagner PL; Kelly RJ; Goel A
Br J Cancer; 2022 Nov; 127(11):2016-2024. PubMed ID: 36097175
[TBL] [Abstract][Full Text] [Related]
19. Antireflux mucoplasty, an evolution of endoscopic antireflux therapy for refractory GERD.
Inoue H; Yamamoto K; Navarro MJ; Ushikubo K; Kimoto Y; Nishikawa Y; Tanabe M; Shimamura Y
VideoGIE; 2023 Nov; 8(11):435-440. PubMed ID: 38026716
[TBL] [Abstract][Full Text] [Related]
20. Current and Future Treatment Strategies for Esophageal Adenocarcinoma.
Quaas A
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33053623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
